TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SANTA CLARA, Calif., Aug. 01, 2017 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, cardiovascular and metabolic disease research, announces the launch of pre-clinical models of inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) to help inform decision making in pre-clinical drug development. These models mark the first of many the company plans to release as part of our commitment to serve autoimmune and inflammatory disease researchers.
CrownBio has developed mechanistically diverse models of RA and IBD to drive pre-clinical drug development. The models have been scientifically designed to evoke the similar clinical features observed in humans suffering from these conditions, making them ideal systems for pre-clinical researchers developing IBD and RA therapeutics.
The IBD models include, acute dextran sodium sulfate (DSS) challenge and T cell transfer models of IBD, develop symptoms indicative of IBD, including weight loss, colon shortening and an associated inflammation in the gut. While RA models include collagen-induced arthritis and collagen antibody-induced arthritis models that develop the clinical features of arthritis including swollen and inflamed joints.
“Millions of patients endure the pain and discomfort caused by RA and IBD,” said Laurie Heilmann, SVP of Global Strategy, Marketing & Business Development. “Our team led by Joel Tocker, Head of Inflammation, has over 40 years of drug discovery experience in autoimmune and inflammatory diseases to help build ideal models that lead to therapeutic advancements.”
“CrownBio is excited to expand the unique advantages of our scientific technology platform into autoimmune and inflammatory disease research,” said Jean Pierre Wery, Chief Executive Officer. “We look forward to growing our therapeutic portfolio in this area and delivering valuable insights which drive new discoveries that bring drugs to market, achieving our mission of connecting science to patients.”
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries: Jody Barbeau Crown Bioscience Inc. [email protected]
